Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Burt

Showing results (161-170 of 182) with videos related to

Pageof 19
Sort By:
Neuro-Oncology|March 13, 2015
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE studyL Burt Nabors, Karen L Fink, Tom Mikkelsen, et al.
Neuro-Oncology Advances|July 10, 2020
Highlights of the inaugural ten - the launch of Neuro-Oncology AdvancesFarshad Nassiri, Kenneth Aldape, Manmeet Alhuwalia, et al.
Neuro-Oncology|June 8, 2020
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug deliveryStuart A Grossman, Carlos G Romo, Michelle A Rudek, et al.
Journal of the Academy of Nutrition and Dietetics|June 15, 2014
A free new dietary supplement label database for registered dietitian nutritionistsJohanna T Dwyer, Leila G Saldanha, Richard A Bailen, et al.
AJNR. American Journal of Neuroradiology|May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 28, 2014
A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responsesJames M Markert, Shantanu N Razdan, Hui-Chien Kuo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiformeDavid A Reardon, Karen L Fink, Tom Mikkelsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2016
Repeatability of <sup>18</sup>F-FLT PET in a Multicenter Study of Patients with High-Grade GliomaMartin A Lodge, Matthias Holdhoff, Jeffrey P Leal, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 29, 2004
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant settingE Antonio Chiocca, Khalid M Abbed, Stephen Tatter, et al.
Neuro-Oncology|July 6, 2019
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patientsCraig Horbinski, Keith L Ligon, Priscilla Brastianos, et al.
Pageof 19

Showing results (161-170 of 182) with videos related to

Sort By:
Pageof 19
Neuro-Oncology|March 13, 2015
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE studyL Burt Nabors, Karen L Fink, Tom Mikkelsen, et al.
Neuro-Oncology Advances|July 10, 2020
Highlights of the inaugural ten - the launch of Neuro-Oncology AdvancesFarshad Nassiri, Kenneth Aldape, Manmeet Alhuwalia, et al.
Neuro-Oncology|June 8, 2020
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug deliveryStuart A Grossman, Carlos G Romo, Michelle A Rudek, et al.
Journal of the Academy of Nutrition and Dietetics|June 15, 2014
A free new dietary supplement label database for registered dietitian nutritionistsJohanna T Dwyer, Leila G Saldanha, Richard A Bailen, et al.
AJNR. American Journal of Neuroradiology|May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 28, 2014
A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responsesJames M Markert, Shantanu N Razdan, Hui-Chien Kuo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2008
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiformeDavid A Reardon, Karen L Fink, Tom Mikkelsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2016
Repeatability of <sup>18</sup>F-FLT PET in a Multicenter Study of Patients with High-Grade GliomaMartin A Lodge, Matthias Holdhoff, Jeffrey P Leal, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 29, 2004
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant settingE Antonio Chiocca, Khalid M Abbed, Stephen Tatter, et al.
Neuro-Oncology|July 6, 2019
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patientsCraig Horbinski, Keith L Ligon, Priscilla Brastianos, et al.
Pageof 19